A novel strategy for the treatment of cocaine addiction.
about
Future pharmacological treatments for substance use disordersNeurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preferenceNeurocircuitry of addictionPositron emission tomography molecular imaging of dopaminergic system in drug addictionStructures of gamma-aminobutyric acid (GABA) aminotransferase, a pyridoxal 5'-phosphate, and [2Fe-2S] cluster-containing enzyme, complexed with gamma-ethynyl-GABA and with the antiepilepsy drug vigabatrinReward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviorsGamma-vinyl GABA, an irreversible inhibitor of GABA transaminase, alters the acquisition and expression of cocaine-induced sensitization in male ratsEffect of add-on valproate on craving in methamphetamine depended patients: A randomized trialGABA(B) receptor gene expression is not altered in cocaine-sensitized rats.Brain imaging research: does the science serve clinical practice?The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.Pharmacological approaches to methamphetamine dependence: a focused review.Novel pharmacotherapeutic treatments for cocaine addiction.The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile sDetermination of GABA, glutamate and carbamathione in brain microdialysis samples by capillary electrophoresis with fluorescence detection.Mechanism of inactivation of γ-aminobutyric acid aminotransferase by (1S,3S)-3-amino-4-difluoromethylene-1-cyclopentanoic acid (CPP-115)Design and mechanism of tetrahydrothiophene-based γ-aminobutyric acid aminotransferase inactivators.(1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.Dopamine in drug abuse and addiction: results from imaging studies and treatment implications.Effects of vigabatrin, an irreversible GABA transaminase inhibitor, on ethanol reinforcement and ethanol discriminative stimuli in mice.Addiction and brain reward and antireward pathways.Mechanism of Inactivation of GABA Aminotransferase by (E)- and (Z)-(1S,3S)-3-Amino-4-fluoromethylenyl-1-cyclopentanoic Acid.S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: a microdialysis study.Cognitive processing of drug-related stimuli: the role of memory and attention.Emerging pharmacological strategies in the fight against cocaine addiction.(+/-)-(1S,2R,5S)-5-Amino-2-fluorocyclohex-3-enecarboxylic acid. A potent GABA aminotransferase inactivator that irreversibly inhibits via an elimination-aromatization pathwayEnantiomers of 4-amino-3-fluorobutanoic acid as substrates for gamma-aminobutyric acid aminotransferase. Conformational probes for GABA bindingGamma-vinyl GABA inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats by a non-dopaminergic mechanismEffects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats.Fluorinated conformationally restricted gamma-aminobutyric acid aminotransferase inhibitorsMechanism-based medication development for the treatment of nicotine dependence.Gamma-vinyl GABA increases nonvesicular release of GABA and glutamate in the nucleus accumbens in rats via action on anion channels and GABA transporters.Review. Neurobiology of nicotine dependence.Hypothesis-driven medication discovery for the treatment of psychostimulant addictionRacemic gamma vinyl-GABA (R,S-GVG) blocks methamphetamine-triggered reinstatement of conditioned place preference.The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers.Influence of positive allosteric modulators on GABA(B) receptor coupling in rat brain: a scintillation proximity assay characterisation of G protein subtypes.Deletion of the GABAA α2-subunit does not alter self administration of cocaine or reinstatement of cocaine seeking.Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-acetylated-alpha-linked-acidic dipeptidase (NAALADASE).Gamma-vinyl GABA (GVG) blocks expression of the conditioned place preference response to heroin in rats.
P2860
Q22242633-83C4D618-4F74-4D4F-B139-3F9FFDDC24EBQ24634249-EDCE4EC7-0676-41D9-991B-E7DE99902F91Q24647156-502F7882-96A6-4E7E-9ED9-6429E7E75FF7Q26992051-FD30317C-AE91-44A8-B33E-39E489F33702Q27642315-7F6E86FB-8308-4FC8-B3D6-6A42AE75EF43Q28209521-81EF8706-5A92-4048-AB73-48DFB61E4935Q28579393-46EAA49A-B5F8-4AEF-BC77-7AC45B862D4CQ28595633-D319E079-AB2D-4537-A610-585459C6458DQ30831596-34B88060-49D9-479A-B9AA-6EAD3106806EQ31131085-6F84A62B-E5BF-4B7F-93F2-13FD23A6461AQ33757216-B2430DDE-3826-4E22-84F6-7C8015A6979CQ33906303-3A70BCEE-F9FC-4280-9B86-8C0CA974E956Q34065088-427661B3-D9DF-40D0-9F12-20A80BBEC9B0Q34240602-1610E8E4-0940-4D34-B35A-E35357D88A8CQ34433835-64944F02-C682-4019-8BC2-5579F452AD73Q35157592-BF014767-C607-4DFF-896D-FD2D81BB9703Q35329906-5D16A6C3-F858-4CED-9B6A-868F66AB53EFQ35670379-6AE4BB73-A4C9-4D6C-84BE-C3C7E4C9B8C7Q35751195-57A4BDD4-F662-4C55-A7B3-96BE02F80FA6Q35812640-8C231AC3-9BA2-40F2-8A14-F62AE0F981FDQ35995170-6F9FECCB-9105-490C-B483-05A5EBF8A80BQ36074460-3375AC50-8AA3-4D2B-AED4-D7C49C19B78CQ36243255-965178F6-5E58-4BE0-98AF-A8EB663B2E4FQ36364227-A7147E7C-C3B4-4B1F-BE5A-FBF5B71D2A64Q36407408-E4475823-ECC6-4B94-AAAD-21334A9872D9Q36944154-ECFD3910-C82A-4068-A805-4130A15F5A5CQ36944163-9549E2AD-86C0-4807-8606-7BA1E6FFA589Q36952331-D4CB03D5-1CAC-496F-9383-69AF75C187DEQ36952858-64279BB5-8B51-49B0-88D8-23399A5A57C7Q36958767-E1BECE0E-1DAF-4ED1-81CD-45AF538B8EF8Q37018610-FF41C8F6-63AD-4293-9192-6BD47A4E83B0Q37018617-FE3CFDC3-E3E8-4F08-83F6-FE21F983B2EEQ37024161-4235FF05-0543-4EAC-ACD3-22B227F0C276Q37183687-E0023EBE-9AFE-4F2A-9083-101A25073380Q37216876-74B7A79C-6BC4-4FD9-B8EA-3D052122E083Q37416909-1F1AD485-3E59-4549-9613-37333A720BFEQ40049789-6AFA118C-01A9-4C79-80BA-47143C4566E8Q40707696-E30F56A7-465A-49B3-8A2A-263816AF51FEQ43608580-E49ECE2C-189A-4001-B0B7-D51F500C87F7Q43629682-085AE3C7-A19E-4F5A-88A7-F1F490966A0F
P2860
A novel strategy for the treatment of cocaine addiction.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
A novel strategy for the treatment of cocaine addiction.
@en
A novel strategy for the treatment of cocaine addiction.
@nl
type
label
A novel strategy for the treatment of cocaine addiction.
@en
A novel strategy for the treatment of cocaine addiction.
@nl
prefLabel
A novel strategy for the treatment of cocaine addiction.
@en
A novel strategy for the treatment of cocaine addiction.
@nl
P2093
P2860
P1433
P1476
A novel strategy for the treatment of cocaine addiction.
@en
P2093
Ashby CR Jr
Gardner EL
Kushner SA
P2860
P304
P356
10.1002/(SICI)1098-2396(199810)30:2<119::AID-SYN1>3.0.CO;2-F
P577
1998-10-01T00:00:00Z